ZYUS's Non-Opioid Pain Drug Shows Promise in Advanced Cancer Trial
Event summary
- ZYUS's Phase 2a UTOPIA-1 trial of Trichomylin® softgel capsules in advanced cancer patients showed clinically relevant pain reduction in 43% of evaluable patients for average pain.
- No treatment-related serious adverse events were observed, supporting the drug's safety profile.
- 29% of evaluable patients required no rescue opioids during Trichomylin® dosing, suggesting potential opioid reduction.
- ZYUS plans to present results at MIPCC 2026 and submit for peer-reviewed publication.
The big picture
ZYUS's positive Phase 2a results for Trichomylin® come amid growing regulatory and clinical focus on non-opioid pain management alternatives. The opioid crisis has created urgent demand for effective, safer pain treatments, particularly for severe cancer-related pain. ZYUS's approach targets a significant unmet need in the $60+ billion global pain management market, with potential to disrupt current opioid-dependent treatment paradigms.
What we're watching
- Regulatory Alignment
- Whether ZYUS can successfully incorporate opioid reduction as a co-primary endpoint in future trials to meet FDA guidance.
- Clinical Progression
- The pace at which ZYUS advances Trichomylin® into larger randomized controlled trials.
- Market Differentiation
- How Trichomylin® positions itself between NSAIDs and opioids in the pain management market.